Liberia Launches Study To Assess Ebola’s Long-Term Health Effects; Drugmakers Struggle To Assess Ebola Vaccines In Clinical Trials Due To Lack Of Qualified Volunteers

Agence France-Presse: Thousands of Liberians in ‘post-Ebola syndrome’ study
“Liberia launched a five-year study on Wednesday to unravel the mystery of the long-term health effects that plague Ebola survivors and assess how long they should go without sex…” (Dosso, 6/17).

Reuters: Ebola vaccines in limbo expose need for more speed in trials
“Drugmakers’ plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa. GlaxoSmithKline, Merck, and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the job and preventing infection…” (Kelland/Hirschler, 6/17).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.